Company Analysis Pulmonx Corporation
1. Summary
Advantages
- Price (6.76 $) is less than fair price (10.8 $)
- Current debt level 22.53% is below 100% and has decreased over 5 years from 40.75%.
Disadvantages
- Dividends (0%) are below the sector average (0.541%).
- The stock's return over the last year (-54.4%) is lower than the sector average (-12.5%).
- The company's current efficiency (ROE=-51.42%) is lower than the sector average (ROE=9.61%)
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| Pulmonx Corporation | Healthcare | Index | |
|---|---|---|---|
| 7 days | -2.4% | 2.5% | 0% |
| 90 days | 1.3% | -17.8% | 2.4% |
| 1 year | -54.4% | -12.5% | 22.4% |
LUNG vs Sector: Pulmonx Corporation has significantly underperformed the "Healthcare" sector by -41.9% over the past year.
LUNG vs Market: Pulmonx Corporation has significantly underperformed the market by -76.82% over the past year.
Stable price: LUNG is not significantly more volatile than the rest of the market on "NASDAQ" over the last 3 months, with typical variations of +/- 5% per week.
Long period: LUNG with weekly volatility of -1.05% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Below fair price: The current price (6.76 $) is lower than the fair price (10.8 $).
Price significantly below the fair price: The current price (6.76 $) is 59.8% lower than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (0) is lower than that of the sector as a whole (48.77).
P/E vs Market: The company's P/E (0) is lower than that of the market as a whole (49.04).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (4.16) is lower than that of the sector as a whole (4.83).
P/BV vs Market: The company's P/BV (4.16) is higher than that of the market as a whole (3.17).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (7.17) is lower than that of the sector as a whole (33.77).
P/S vs Market: The company's P/S indicator (7.17) is lower than that of the market as a whole (10.24).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (-7.5) is higher than that of the sector as a whole (-22.17).
EV/Ebitda vs Market: The company's EV/Ebitda (-7.5) is lower than that of the market as a whole (28.32).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Rising and has grown by 17.79% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (17.79%).
Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (4135.44%).
5.4. ROE
ROE vs Sector: The company's ROE (-51.42%) is lower than that of the sector as a whole (9.61%).
ROE vs Market: The company's ROE (-51.42%) is lower than that of the market as a whole (10.71%).
5.5. ROA
ROA vs Sector: The company's ROA (-34%) is lower than that of the sector as a whole (0.3443%).
ROA vs Market: The company's ROA (-34%) is lower than that of the market as a whole (6.47%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (-22.89%) is lower than that of the sector as a whole (7.63%).
ROIC vs Market: The company's ROIC (-22.89%) is lower than that of the market as a whole (10.79%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '0.541%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
8. Insider trades
8.1. Insider trading
Insider Selling More insider purchases by 100% over the last 3 months.
8.2. Latest transactions
| Transaction date | Insider | Type | Price | Volume | Quantity |
|---|---|---|---|---|---|
| 02.12.2024 | Lehman David Aaron GENERAL COUNSEL |
Sale | 6.19 | 34 026 | 5 497 |
| 02.12.2024 | Rose Geoffrey Beran CHIEF COMMERCIAL OFFICER |
Sale | 6.18 | 27 044 | 4 376 |
| 24.06.2024 | Rose Geoffrey Beran CHIEF COMMERCIAL OFFICER |
Sale | 6.16 | 7 293 | 1 184 |
| 22.04.2024 | Rose Geoffrey Beran CHIEF COMMERCIAL OFFICER |
Sale | 7.49 | 8 868 | 1 184 |
| 01.03.2024 | McKune John INTERIM CFO |
Sale | 9.06 | 9 767 | 1 078 |
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
